

# Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

NCT03850418

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Henry Ford Health System
Enrollment	43 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- Patients with AML/MDS/MPN, CMML post Allogeneic SCT who experience any drop in total or myeloid chimerism any time after day 30, or their day 30 or day100 myeloid donor chimerism is below 98% without concurrent hematologic relapse (that is, patients with  $\lt 5\%$  bone marrow blasts as obtained at that time point) will be offered treatment with azacitidine
- $\geq 30$  -180 days post SCT and patients must have ANC  $\gt 1000$ , PLT  $\gt 50,000$
- Age 18-75 years old
- Performance score of at least 70% by Karnofsky
- Adequate kidney and liver function as demonstrated by:  
... and 5 more (see full listing online)

### Exclusion (5)

- Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause
- Active or prior CNS leukemia, unless in complete remission for at least 2 months.
- History of serious chronic mental disorder or drug-abuse accompanied by documented problems of compliance with therapeutic programs.
- Uncontrolled infection
- Grade III, IV graft versus host disease (GVHD)

## Locations (1 total)

---

Henry ford hospital, Detroit, Michigan, United States